10 results about "Pinoresinol" patented technology

The invention belongs to the technical field of medicines, and particularly relates to forsythiaside glucosamine, a preparation method thereof and application of the forsythiaside glucosamine in treatment of osteoarthritis. The invention relates to design and synthesis of forsythiaside glucosamine, and researches on the treatment effect of forsythiaside glucosamine on an osteoarthritis mouse model. In the structural general formula of the compound, R1 is an amino group, a phthaloyl amino group or an allyloxy amido group, R2, R3 and R4 groups represent a hydroxyl group or an alkanoyloxy group, and the configurations of different head positions are alpha and beta. Wherein the alkanoyloxy group is a C1-C6 alkanoyloxy group or a deuterated alkanoyloxy group. The synthesized forsythiaside glucosamine is used as a twin drug, and shows better cartilage generation promoting activity and anti-inflammatory activity compared with combined use of forsythiaside and glucosamine on an osteoarthritis mouse model. In addition, under the same administration dosage, the activity of promoting cartilage generation and the like is obviously superior to that of forsythiaside acetylglucosamine in the prior art.

The invention relates to a method for extracting, separating and preparing pinoresinol-beta-D-glucoside from tubers of zornia gibbosa. The method comprises the following specific steps: adding an ethanol-water solution into a zornia gibbosa tuber for extraction, concentrating an extracting solution, adding ethanol for alcohol precipitation, enriching supernate through macroporous adsorption resin, decolorizing through an ion resin material, and crystallizing and recrystallizing a decolorizing solution to obtain the high-purity pinoresinol-beta-D-glucoside (the purity is greater than 97%). The process flow provided by the invention is simple, the transfer rate is high, and large-scale preparation and industrial production can be stably and repeatedly realized; the process is green and environment-friendly, only ethanol is used as a solvent and can be recycled, the cost is reduced, and the environmental pollution is small.

The present invention discloses a yeast mutualistic symbiotic community for de novo synthesis of lignin glycosides, its construction method and application, which relates to the technical field of synthetic biology. The key technical points of the technical solution are that the present invention constructs a Saccharomyces cerevisiae symbiotic community for the first time, and heterologously synthesizes complex antiviral active lignin glycosides of plant origin using simple carbon sources. In the early stage, a Saccharomyces cerevisiae cell factory with high production of ferulic acid and efficient conversion of ferulic acid to synthesize lignin glycosides was constructed. Methionine and adenosine auxotrophies were respectively constructed in the two cell factories to achieve the optimal auxotrophic pair to form a symbiotic community, and successfully achieved de novo synthesis of antiviral active lignin glycosides with glucose as the sole carbon source, including recteoside B, pinoresinol monoglycoside and pinoresinol diglycoside. The present invention uses a microbial symbiotic community to synthesize lignin glycosides in one step, providing a strong research and application basis for subsequent synthesis of other high-value complex active components using the mutually beneficial symbiotic Saccharomyces cerevisiae flora.

The present invention relates to a method for extracting, separating and preparing pinoresinol-β-D-glucoside from tubers of dianthus sinensis. The specific steps of the method are: extracting the tubers of dianthus sinensis with an ethanol-water solution, concentrating the extract and adding ethanol for alcohol precipitation, taking the supernatant and enriching it with a macroporous adsorption resin and decolorizing it with an ionic resin material, and then crystallizing and recrystallizing the decolorized liquid to obtain high-purity pinoresinol-β-D-glucoside (purity greater than 97%). The process provided by the present invention is simple, has a high transfer rate, and can stably and repeatedly achieve large-scale preparation and industrial production; the process is green and environmentally friendly, uses only ethanol as a solvent, can be recycled and reused, reduces costs and has little pollution to the environment.

The present invention discloses a pharmaceutical composition for preventing and treating non-alcoholic fatty liver disease. The pharmaceutical composition comprises the following components: magnolol, gentisic acid, baicalin, syringin, wogonoside, honokiol, prunasin, and pinoresinol 4-O-β-glucoside, wherein the mass ratio between the magnolol, the gentisic acid, the baicalin, the syringin, the wogonoside, the honokiol, the prunasin, and the pinoresinol 4-O-β-glucoside is (5.00 to 33.00):(12.00 to 110.00):(12.00 to 110.00):(4.50 to 42.00):(2.00 to 9.00):(0.10 to 1.10):(0.80 to 5.50):(6.00 to 40.00). The pharmaceutical composition of the present invention can improve macrovesicular steatosis, inflammatory cell infiltration and ballooning degeneration of hepatocytes, and can be used for preventing and treating non-alcoholic fatty liver disease.

The present application provides a kind of lignan composition for resisting osteoporosis and its application, the composition is composed of pinoresinol diglucoside, dehydrodiconiferyl alcohol-4, γ'-bis-O-β-D-glucopyranoside, pinoresinol monoglucoside component;The mass ratio of pinoresinol diglucoside: dehydrodiconiferyl alcohol-4, γ'-bis-O-β-D-glucopyranoside: pinoresinol monoglucoside is 1:0.1-0.3:0.2-0.4.The lignan composition provided by the present application is stable in quality, high in safety, suitable for long-term taking, and has good effect on treating osteoporosis.The composition can be used for senile osteoporosis, and has more significant effect on inhibiting bone density reduction in ovary-removed female rat osteoporosis model.

The invention discloses application of pinoresinol in treatment of rectal cancer, it is found for the first time that the pinoresinol can inhibit expression of CaLM1, then CaLM1 / CaMKII / CREB signaling pathways can be inhibited by reducing expression levels of CAMKII and p-CREB, and on the basis of the inhibition of the expression levels of CAMKII and p-CREB, the application of the pinoresinol in treatment of rectal cancer is achieved. The pinoresinol is used as an inhibitor of a CaLM1 / CaMKII / CREB signal channel for the first time, in-vitro and in-vivo effects on rectal cancer cells and solid tumors thereof are experimented, and it is found that in-vitro pinoresinol dose dependence reduces expression of CaLM1, CaMKII and p-CREB, proliferation of cancer cells is remarkably inhibited, apoptosis of the cancer cells is promoted, and the tumor cell cycle is retarded in the G0 / G1 phase. In-vivo experiments show that the volume and weight of tumors are reduced by dosages of the pinoresinol, and the experiments find that the rectal cancer inhibition effect of the high-concentration pinoresinol (20.0 mg / kg) is close to that of a known chemotherapeutic drug cis-platinum (8.0 mg / kg) with a curative effect; in addition, the TUNEL experiment and the immunohistochemical analysis further support the apoptosis promoting and anti-proliferation effects of the pinoresinol by inhibiting the CaLM1 / CaMKII / CREB signal channel.

The invention relates to a method for extracting pinoresinol from herba ephedrae, which can effectively extract pinoresinol from herba ephedrae and realize the application in preparation of medicines for treating pulmonary arterial hypertension, and the preparation method comprises the following steps: taking dried roots and rhizomes of herba ephedrae, and carrying out water extraction and vacuum concentration to obtain an extract; and dispersing with water, eluting, dissolving with methanol, stirring with silica gel, carrying out gradient elution, detecting and identifying, merging the same fractions, loading the target components on column chromatography, eluting, separating and purifying, collecting the fractions with retention time, and drying to obtain the pinoresinol. The pinoresinol prepared by the invention has the effect of resisting abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs), and realizes the application in preparation of medicines for treating pulmonary arterial hypertension. The preparation method is simple, the medicinal value of the pinoresinol and the medicinal value of the herba ephedrae are easily and industrially prepared, the application of the pinoresinol in preparation of the medicine for treating the pulmonary arterial hypertension is realized, and the medicine is a great innovation in preparation of the medicine for treating the pulmonary arterial hypertension and has practical popularization and application values.

The application belongs to the field of traditional Chinese medicines, and provides a method for constructing a kidney-strengthening tablet fingerprint spectrum, which comprises: detecting test sample solution and reference material solution by HPLC, wherein the chromatographic conditions are as follows: using octadecylsilane bonded silica gel as a filler; using acetonitrile as mobile phase A and 0.05% formic acid water as mobile phase B, and identifying 13 chromatographic peaks, which are 5-hydroxymethyl furfural, morroniside, motherwort alkaloid hydrochloride, loganin, pinoresinol di-glucoside, paeoniflorin, salvianolic acid B, psoralen, isopsoralen, paeonol, cryptotanshinone, tanshinone I and tanshinone IIA, so that the quality of the kidney-strengthening tablet can be comprehensively and accurately characterized. Meanwhile, the detection method in the application is stable and feasible. The characteristic spectrum established by the application can comprehensively reflect the complex chemical components and relative proportions of the kidney-strengthening tablet, and can effectively characterize the quality of the medicine.

The present application belongs to the field of agriculture, and provides application of pinoresinol in inhibiting bacteria, inducing Panax notoginseng to produce resistance, relieving Panax notoginseng leaf disease and / or promoting Panax notoginseng growth, and further provides a method for inhibiting bacteria, inducing Panax notoginseng to produce resistance, relieving Panax notoginseng leaf disease and / or promoting Panax notoginseng growth, and a biological pesticide, a Panax notoginseng resistance inducer and a Panax notoginseng growth regulator. Research shows that within a certain concentration range, pinoresinol can not only directly inhibit the growth of Alternaria panax, but also stimulate the plant to produce resistance, induce the synthesis of jasmonic acid, salicylic acid and auxin plant hormones, enhance the resistance of Panax notoginseng to leaf black spot, and regulate the growth and development of Panax notoginseng. Compared with other biological pesticides, inducers and growth regulators, the pinoresinol has the characteristics of non-toxic, non-polluting and environment-friendly, and is an effective way for Panax notoginseng green ecological prevention and control.